Evidence map›Paper›PMID 41568045›Full record

ArticleFrontiers in microbiology2025

The effect and safety of small-molecule antiviral drugs on long prognosis of post-COVID-19 pulmonary fibrosis: a real-world study in China.

Yilin Xu, Ming Lu, Yawei Li, Xiaoling Den, Dechang Peng, Fuqing Zhou, Anqi Li, Tieying Hou, Tianxin Xiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yilin Xu *Infection Control and Prevention Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Ming Lu *China-Japan Friendship Jiangxi Hospital, National Regional Center for Respiratory Medicine, Nanchang, China.
Yawei Li *China-Japan Friendship Jiangxi Hospital, National Regional Center for Respiratory Medicine, Nanchang, China.
Xiaoling DenJiangxi Provincial Key Laboratory of Prevention and Treatment of Infectious Diseases, Nanchang, China.
Dechang PengMedical Imaging Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Fuqing ZhouMedical Imaging Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Anqi LiChina-Japan Friendship Jiangxi Hospital, National Regional Center for Respiratory Medicine, Nanchang, China.
Tieying HouMedical Experimental Center, Shenzhen Nanshan People's Hospital, The 6th Affiliated Hospital of Shenzhen University Medical School, Shenzhen, China.
Tianxin XiangInfection Control and Prevention Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Post-COVID-19 pulmonary fibrosis (PCPF) is one of the most common diagnoses after COVID-19 acute infection. However, the interventions for long-term prognosis of PCPF are relatively lacking. Aim: We aimed to observe one-year readmission and mortality rates among patients with PCPF, and tried to explore the impact of small-molecule antiviral drugs (SMADs) during hospitalization on the prognosis. Method: A total of 372 patients diagnosed as PCPF were enrolled. 293 of them treated with SMADs and the remaining 79 treated with NO SMADs. One-year readmission and mortality rates were evaluated via regression analysis. Results: During hospitalization, 16 of the 372 patients died. An additional 19 survivors died within one-year postdischarge. Among survivors, 49.62% were readmitted. Compared to the NO-SMAD group, the SMAD group presented a lower one-year readmission rate (45.97%vs. 63.64%, Conclusion: Nearly half of PCPF patients experienced readmission within one-year following their initial hospitalization for acute COVID-19. Importantly, treatment with SMADs during the acute infection phase was significantly associated with a reduced readmission rate.

Indexed as

COVID-19post-COVID-19 pulmonary fibrosisprognosispulmonary fibrosissmall-molecule antiviral drug

Identifiers

PMID41568045
PMCPMC12816351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.